BioCentury | Nov 3, 2017
Company News

Boehringer and Gubra partner to develop food intake regulators

...Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Gubra ApS (Horsholm, Denmark) to jointly identify and develop peptides...
...plus double-digit royalties. Gubra ApS, Horsholm, Denmark Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Endocrine/Metabolic Shannon Lehnbeuter Boehringer Ingelheim GmbH Gubra ApS...
BioCentury | Sep 30, 2013
Company News

Gubra ApS, Sanofi deal

...Gubra said it uses solid phase peptide synthesis to create peptides with improved pharmacological properties. Gubra ApS...
BioCentury | Sep 24, 2013
Company News

Gubra, Sanofi in peptide deal

Gubra ApS (Horsholm, Denmark) partnered with Sanofi (Euronext:SAN; NYSE:SNY) to discover and develop peptide-based drugs for diabetes and obesity. Gubra said the deal builds on an existing research consortium between the biotech, Gentofte Hospital (Hellerup,...
Items per page:
1 - 3 of 3
BioCentury | Nov 3, 2017
Company News

Boehringer and Gubra partner to develop food intake regulators

...Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Gubra ApS (Horsholm, Denmark) to jointly identify and develop peptides...
...plus double-digit royalties. Gubra ApS, Horsholm, Denmark Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Endocrine/Metabolic Shannon Lehnbeuter Boehringer Ingelheim GmbH Gubra ApS...
BioCentury | Sep 30, 2013
Company News

Gubra ApS, Sanofi deal

...Gubra said it uses solid phase peptide synthesis to create peptides with improved pharmacological properties. Gubra ApS...
BioCentury | Sep 24, 2013
Company News

Gubra, Sanofi in peptide deal

Gubra ApS (Horsholm, Denmark) partnered with Sanofi (Euronext:SAN; NYSE:SNY) to discover and develop peptide-based drugs for diabetes and obesity. Gubra said the deal builds on an existing research consortium between the biotech, Gentofte Hospital (Hellerup,...
Items per page:
1 - 3 of 3